ARHGAP15 promotes metastatic colonization in gastric cancer by suppressing RAC1-ROS pathway

PLoS Genet. 2023 Feb 21;19(2):e1010640. doi: 10.1371/journal.pgen.1010640. eCollection 2023 Feb.

Abstract

The molecular mechanism of tumor metastasis, especially how metastatic tumor cells colonize in a distant site, remains poorly understood. Here we reported that ARHGAP15, a Rho GTPase activating protein, enhanced gastric cancer (GC) metastatic colonization, which was quite different from its reported role as a tumor suppressor gene in other cancers. It was upregulated in metastatic lymph nodes and significantly associated with a poor prognosis. Ectopic expression of ARHGAP15 promoted metastatic colonization of gastric cancer cells in murine lungs and lymph nodes in vivo or protected cells from oxidative-related death in vitro. However, genetic downregulation of ARHGAP15 had the opposite effect. Mechanistically, ARHGAP15 inactivated RAC1 and then decreased intracellular accumulation of reactive oxygen species (ROS), thus enhancing the antioxidant capacity of colonizing tumor cells under oxidative stress. This phenotype could be phenocopied by inhibition of RAC1 or rescued by the introduction of constitutively active RAC1 into cells. Taken together, these findings suggested a novel role of ARHGAP15 in promoting gastric cancer metastasis by quenching ROS through inhibiting RAC1 and its potential value for prognosis estimation and targeted therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Down-Regulation
  • Mice
  • Oxidative Stress
  • Reactive Oxygen Species / metabolism
  • Stomach Neoplasms* / genetics
  • rac1 GTP-Binding Protein / genetics

Substances

  • Reactive Oxygen Species
  • rac1 GTP-Binding Protein

Grants and funding

XYG is supported by General Research Fund from Hong Kong Research Grant Council (17143716), Collaborative Research Funds (C7065-18GF, C7026-18GF and C4039-19GF), Research Impact Funds (R4017-18, R1020-18F and R7022-20), National Natural Science Foundation of China (81772554, 82072738), the Shenzhen Science and Technology Program (KQTD20180411185028798) and the Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2019BT02Y198). Professor XYG is Sophie YM Chan Professor in Cancer Research. CJ is supported by the National Natural Science Foundation of China (82002468). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.